Geode Capital Management LLC Has $50.71 Million Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Geode Capital Management LLC boosted its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 1.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 550,260 shares of the medical instruments supplier's stock after purchasing an additional 7,737 shares during the quarter. Geode Capital Management LLC owned 2.45% of LeMaitre Vascular worth $50,711,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Franklin Resources Inc. lifted its position in LeMaitre Vascular by 8.2% in the 4th quarter. Franklin Resources Inc. now owns 13,678 shares of the medical instruments supplier's stock valued at $1,260,000 after acquiring an additional 1,032 shares in the last quarter. Alliancebernstein L.P. grew its holdings in shares of LeMaitre Vascular by 6.0% during the fourth quarter. Alliancebernstein L.P. now owns 22,584 shares of the medical instruments supplier's stock worth $2,081,000 after buying an additional 1,287 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in LeMaitre Vascular by 239.5% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 9,833 shares of the medical instruments supplier's stock valued at $906,000 after buying an additional 6,937 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in LeMaitre Vascular by 45.9% in the 4th quarter. JPMorgan Chase & Co. now owns 147,489 shares of the medical instruments supplier's stock valued at $13,590,000 after acquiring an additional 46,430 shares in the last quarter. Finally, EntryPoint Capital LLC grew its stake in shares of LeMaitre Vascular by 58.2% during the 4th quarter. EntryPoint Capital LLC now owns 4,440 shares of the medical instruments supplier's stock worth $409,000 after acquiring an additional 1,633 shares in the last quarter. Institutional investors own 84.64% of the company's stock.

Remove Ads

LeMaitre Vascular Stock Up 1.0 %

Shares of LMAT stock traded up $0.85 during trading hours on Tuesday, reaching $84.63. The company's stock had a trading volume of 145,216 shares, compared to its average volume of 159,602. LeMaitre Vascular, Inc. has a fifty-two week low of $62.39 and a fifty-two week high of $109.58. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of 46.25, a PEG ratio of 2.22 and a beta of 0.89. The firm's 50 day simple moving average is $88.88 and its 200-day simple moving average is $93.68.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting the consensus estimate of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. Sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were paid a $0.20 dividend. The ex-dividend date was Thursday, March 13th. This represents a $0.80 annualized dividend and a dividend yield of 0.95%. This is an increase from LeMaitre Vascular's previous quarterly dividend of $0.16. LeMaitre Vascular's dividend payout ratio is currently 41.24%.

Wall Street Analyst Weigh In

LMAT has been the subject of several recent research reports. Lake Street Capital increased their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price target on the stock. Oppenheimer lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Finally, Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Five investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, LeMaitre Vascular has a consensus rating of "Moderate Buy" and a consensus target price of $95.25.

Insider Activity at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 2,009 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the transaction, the insider now directly owns 5,564 shares of the company's stock, valued at $456,915.68. This trade represents a 26.53 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 10.79% of the stock is owned by company insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.